BH-002
- Generic Name
- BH-002
Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06231277
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath